Oleclumab - AstraZeneca
Alternative Names: Anti-CD73 mAb - AstraZeneca; Anti-CD73 monoclonal antibody - AstraZeneca; MEDI-9447Latest Information Update: 02 Aug 2024
At a glance
- Originator MedImmune
- Developer AstraZeneca; MedImmune
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Breast cancer; Pancreatic cancer; Sarcoma
- Phase I Solid tumours
- Discontinued Bladder cancer; Colorectal cancer; Ovarian cancer; Prostate cancer
Most Recent Events
- 31 Jul 2024 Discontinued - Phase-I for Bladder cancer (Combination therapy, In the elderly, Neoadjuvant therapy, In adults) in USA (IV) prior to July 2024 (AstraZeneca pipeline, July 2024)
- 31 Jul 2024 Discontinued - Phase-I/II for Colorectal cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Canada, Spain, Australia, USA (IV) prior to July 2024 (AstraZeneca pipeline, July 2024)
- 31 Jul 2024 Discontinued - Phase-II for Ovarian cancer (Combination therapy, Second-line therapy or greater) in Finland, Norway, Denmark (IV) prior to July 2024 (AstraZeneca pipeline, July 2024)